Abstract:Funding Acknowledgements None. Background and purpose MicroRNAs (miRs) have emerged as potential therapeutic targets in cardiovascular disease, given their ability to modulate multiple signaling pathways and cellular processes. Neointima formation as an angioplasty-related complication remains a major issue calling for innovative therapeutic options and is predominantly mediated by phenotypic and functional changes of vascular smooth muscle cells. Here, we propose that targeting miR-31-5p might be an effective approach to selectively modulate smooth muscle cell functions to enhance vascular healing and regeneration. Methods C57J/BlL6 mice (n=6, 3 months, male) were subjected to wire-induced femoral artery injury. At days 10 and 21 after injury, femoral arteries were harvested for miRNA analysis. Expression levels of miR-31-5p were confirmed by qRT-PCR in human coronary artery endothelial cells (HCAEC) and -smooth muscle cells (HCASMC). Further, the effect of miR-31-5p on cellular functions was investigated on HCAECs and HCASMCs in vitro, including migration (scratch assay), proliferation (BrdU assay), and apoptosis. Possible targets of miR-31-5p were identified in silico by structured literature research and target binding prediction and confirmed on mRNA and protein levels. High-resolution microscopy analysis was used to investigate morphological changes. Results Expression analysis revealed a significant upregulation of miR-31-5p (p<0.0001) in murine femoral artery neointimal tissue at 7 and 21 days. In vitro, miR-31-5p was significantly upregulated in HCASMC (p<0,05) but not HCAEC following serum stimulation. On a functional level, miR-31-5p revealed dissenting effects on HCAEC and HCASMC. Whereas migration and proliferation are not altered in HCAECs, knockdown of miR-31-5p significantly reduced migration (p<0,01), proliferation (p<0,05), and increased apoptosis (p<0,05) in HCASMCs. Additionally, the knockdown of miR-31-5p influenced the phenotypical switch of HCASMC towards a contractile phenotype. Under these conditions, the release of cytokines like TNF-alpha and IL1-beta was also significantly reduced (p<0,05) in HCASMCs. Systematic in silico target screens suggested DKK1 and PIAS3 as potential direct targets. Indeed, knockdown of miR-31-5p resulted in a significant upregulation of DKK1 in HCASMC (p<0,05) on mRNA level and DKK1 (p<0,05) and PIAS3 (p<0,05) on mRNA and protein level. An overexpression resulted in a significant downregulation of DKK1 in HCASMC (p<0,05) on mRNA level. Conclusion In conclusion, we report that miR-31-5p is robustly upregulated during neointima formation and seems to exert a functional neointima formation-promoting role in HCASMC rather than HCAEC. Mechanistically, DKK1 and PIAS3 as direct targets of miR-31-5p can mediate the observed effects. Thus, miR-31-5p might represent an attractive target to selectively modulate HCASMC dysfunction following vascular intervention, limiting neointima formation in treated vessels.

MicroRNA-146a sponge therapy suppresses neointimal formation in rat vein grafts.

MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts

Adenovirus-Mediated Gene Transfer Of Microrna-21 Sponge Inhibits Neointimal Hyperplasia In Rat Vein Grafts

MicroRNA-365 Promotes the Contractile Phenotype of Venous Smooth Muscle Cells and Inhibits Neointimal Formation in Rat Vein Grafts.

Inhibition of Neointimal Hyperplasia in Balloon-Induced Vascular Injuries in a Rat Model by Mir-22 Loading Laponite Hydrogels.

MicroRNA-92a -mediated endothelial to mesenchymal transition controls vein graft neointimal lesion formation

microRNA-18a-5p promotes vascular smooth muscle cell phenotypic switch by targeting Notch2 as therapeutic targets in vein grafts restenosis

Microrna-33 Protects Against Neointimal Hyperplasia Induced by Arterial Mechanical Stretch in the Grafted Vein

miR-16-5p Is a Novel Mediator of Venous Smooth Muscle Phenotypic Switching

Upregulation of Mir‑423 Improves Autologous Vein Graft Restenosis Via Targeting ADAMTS‑7.

The effect of lncRNA MIR155HG-modified MSCs and exosome delivery to synergistically attenuate vein graft intimal hyperplasia

Local Gene Transfer of Tissue Inhibitor of Metalloproteinase-2 Influences Vein Graft Remodeling in a Mouse Model

miRNA-126-3p carried by human umbilical cord mesenchymal stem cell enhances endothelial function through exosome-mediated mechanisms in vitro and attenuates vein graft neointimal formation in vivo

Arterial Cyclic Stretch Regulates Lamtor1 and Promotes Neointimal Hyperplasia Via Circslc8a1/mir-20A-5p Axis in Vein Grafts.

Inhibition of Neointima Hyperplasia of Mouse Vein Grafts by Locally Applied Suramin

Empirical Study of Transfecting Early Growth Response Gene‐1 DNA Enzyme to Prevent Intimal Hyperlasia of Autogenous Vein Graft in Rats

A Novel Promising Therapy for Vein Graft Restenosis: Overexpressed Nogo-B Induces Vascular Smooth Muscle Cell Apoptosis by Activation of the JNK/p38 MAPK Signaling Pathway.

MicroRNA-146a regulates angiogenesis and functional regeneration after myocardial infarction

MicroRNA-31-5p is upregulated during neointima formation and influences human coronary artery smooth muscle cell functions by regulating PIAS3 and DKK1

Rapamicina Em Combinação Com A-Cianoacrilato Contribui À Inibição De Hiperplasia Intimal Em Modelos Em Ratos

Local Applied Slow-Releasing Rapamycin Inhibits Neointima Hyperplasia in Vein Graft